Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesNSE:THYROCARE +3.48%87 Return-on-Tangible-Equity is 44.07% as of Jun. 2026, which is 60% above its 10-year median of 27.57. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹412.47 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 81.15% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Thyrocare Technologies's annualized net income for the quarter that ended in Jun. 2026 was ₹2,088 Mil. Thyrocare Technologies's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹4,737 Mil. Therefore, Thyrocare Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 44.07%.
The historical rank and industry rank for Thyrocare Technologies's Return-on-Tangible-Equity or its related term are showing as below:
NSE:THYROCARE'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.88 Med: 27.57 Max: 46.88
Current: 39.79
During the past 13 years, Thyrocare Technologies's highest Return-on-Tangible-Equity was 46.88%. The lowest was 14.88%. And the median was 27.57%.
NSE:THYROCARE's Return-on-Tangible-Equity is ranked better than 81.15% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.33
vs NSE:THYROCARE: 39.79
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Thyrocare Technologies Return-on-Tangible-Equity Related Terms
Thyrocare Technologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 44.07% mean?
Thyrocare Technologies (NSE:THYROCARE) has a Return-on-Tangible-Equity of 44.07% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Thyrocare Technologies and its competitors. This is 60% above median its historical median of 27.57. Over the past decade, Thyrocare Technologies' Return-on-Tangible-Equity has ranged from 14.88 to 46.88. According to the industry distribution chart, Thyrocare Technologies ranks #36 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 18.8%.
Is Thyrocare Technologies' Return-on-Tangible-Equity too high?
Thyrocare Technologies' current Return-on-Tangible-Equity of 44.07% is 60% above median its 10-year median of 27.57. Over the past 10 years, this metric has ranged from a low of 14.88 to a high of 46.88. Based on the distribution chart, Thyrocare Technologies ranks #36 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #36 out of 191 companies for Return-on-Tangible-Equity. This places Thyrocare Technologies in the top 19% of its industry — outperforming the majority of peers. Historically, Thyrocare Technologies' own Return-on-Tangible-Equity has ranged from 14.88 to 46.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current Return-on-Tangible-Equity is 44.07%, which is 60% above median its own 10-year median of 27.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹412.47, compared to a current price of ₹564.25 — trading 36.8% above its estimated fair value. The current Return-on-Tangible-Equity is 44.07%, which is 60% above median its 10-year median of 27.57. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Return-on-Tangible-Equity is 44.07% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹564.25 is trading 36.8% above its estimated GF Value™ of ₹412.47.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Return-on-Tangible-Equity: 44.07% (60% above median its 10-year median of 27.57)
GF Value™: ₹412.47 vs. price of ₹564.25 (36.8% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
